ParagonCare to acquire Haju Medical

• Paragon Care to acquire 100% of Haju Medical, a leading provider of medical aesthetic services and technology in Indonesia
• Total consideration of A$70 million, with A$30 million upfront and remaining balance over 2 years
• Haju Medical reported annual revenue of A$30 million and EBITDA of A$7.7 million for FY24
• Acquisition expected to be earnings accretive for Paragon Care in FY26

Paragon Care Limited (ASX:PGC), a leading healthcare wholesaler, distributor, and manufacturer throughout the Asia Pacific region, has announced that its wholly-owned subsidiary, Paragon Care Singapore Pte. Ltd, has entered into a binding share purchase agreement to acquire 100% of the issued shares in PT Haju Medical Indonesia and Insightof Co., Ltd (collectively, 'Haju Medical' or 'Haju'). Haju Medical is a leading provider of medical aesthetic services and technology in the Indonesian market. Established in 2014, Haju has consistently supported Indonesian clinics and dealers by providing marketing materials, product information, and workshops led by respected aesthetic doctors (or experts) from South Korea. Additionally, Haju operates a buying house in South Korea to secure the best possible aesthetics products for export to Indonesia. The total consideration (before adjustment) for the Acquisition is A$70 million, with A$30 million to be paid upfront on completion and the remaining balance to be paid over approximately 2 years post-completion, subject to minimum EBITDA targets being achieved. Haju reported annual revenue of A$30 million and EBITDA of A$7.7 million for the financial year ending on 31 December 2024. The acquisition is anticipated to be earnings accretive for Paragon Care in FY26. The acquisition will be funded via the previously announced working capital facilities in New Zealand and Thailand, along with surplus cash available within the Paragon Care Group. The completion of the Acquisition is subject to several customary conditions, including obtaining merger filing clearance in South Korea, securing the necessary change of control consents from counterparties, and completing pre-acquisition announcements and creditor clearance in Indonesia. Paragon Care expects to complete this acquisition on or around 30 January 2026.

Haju Medical reported annual revenue of A$30 million and EBITDA of A$7.7 million for the financial year ending on 31 December 2024. The acquisition is anticipated to be earnings accretive for Paragon Care in FY26.